StockData
Amgen Inc logo

Amgen Inc

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)

Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%

Amgen Other Segment Items by Quarter

Other Segment Items (Other Operating Expenses & Non-Core Items) ($M) ($M)

QuarterlyAnnual

Amgen Other Segment Items: $314M in Q2 2026, down 43.6% from a year earlier.

Latest, Q2 2026
314
Period ended Jun 30, 2026
Change on a year earlier
-43.6%
557 in Q2 2025
History
10 quarters
Since Q1 2024
Sources
6
Documents cited below

Where the Q2 2026 figure comes from

Source: Form 10-Q (filed 2026-08-05) ↗

Reported in Form 10-Q / 10-K Note 2 Segment Expense Disaggregation (XBRL).

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedOther Segment Items (Other Operating Expenses & Non-Core Items) ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026314-43.6%Form 10-Q (filed 2026-08-05) ↗
Q1 2026Mar 31, 2026-87-84.5%Form 10-Q (filed 2026-05-01) ↗
Q4 2025Dec 31, 2025745-21.4%Form 10-K (filed 2026-02-13) ↗
Q3 2025Sep 30, 2025-1,642-1.1%Form 10-Q (filed 2025-11-05) ↗
Q2 2025Jun 30, 2025557+25.2%Form 10-Q (filed 2026-08-05) ↗
Q1 2025Mar 31, 2025-562-208.1%Form 10-Q (filed 2026-05-01) ↗
Q4 2024Dec 31, 2024948–Form 10-K (filed 2026-02-13) ↗
Q3 2024Sep 30, 2024-1,661–Form 10-Q (filed 2025-11-05) ↗
Q2 2024Jun 30, 2024445–Form 10-Q (filed 2025-08-06) ↗
Q1 2024Mar 31, 2024520–Form 10-Q (filed 2025-05-02) ↗

Cite this data

StockData. (2026). Amgen Other Segment Items ($M), quarterly Q1 2024–Q2 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/seg-other-exp

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.